trending Market Intelligence /marketintelligence/en/news-insights/trending/lxfi7lqspbobh2j2yowzia2 content esgSubNav
In This List

CorMedix's drug gets FDA orphan drug status for rare cancer

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


CorMedix's drug gets FDA orphan drug status for rare cancer

The U.S. Food and Drug Administration granted orphan drug designation to CorMedix Inc.'s taurolidine to treat neuroblastoma, a type of cancer that forms in certain types of nerve tissues.

Neuroblastoma is a severe form of cancer that most often begins in the adrenal glands, which are the small glands on top of the kidneys. It can develop in the chest, stomach, neck, pelvis, or bones.

This type of cancer occurs mostly in infants and young children.

The agency grants orphan drug designation to therapies for rare diseases that affect fewer than 200,000 people in the U.S.